Preliminary Findings of a Dedicated Ocular Myasthenia Gravis Rating Scale: The OMGRate
- 9 October 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Neuro-Ophthalmology
- Vol. 44 (3), 148-156
- https://doi.org/10.1080/01658107.2019.1660686
Abstract
There is a pressing need for a robust rating scale for ocular myasthenia gravis (OMG). Rating scales for myasthenia gravis (MG) research have a predominant focus on generalised disease. We present results of the first dedicated rating scale for OMG: the ocular myasthenia gravis rating scale (OMGRate). The OMGRate was developed through an international collaboration between neuromuscular and neuro-ophthalmology experts in OMG. It comprises two components: a physician- examination (OMGRate-e) and a patient questionnaire (OMGRate-q).. The OMGRate was prospectively validated in patients attending a neuro-ophthalmology clinic from April 2017 to October 2018. External validity and reliability of OMGRate were evaluated using validated MG rating scales: the Myasthenia Gravis Composite (MGC), the Myasthenia Gravis Quality of Life (MG-QOL), and the ocular component from the Myasthenia Gravis Impairment Index questionnaire (MGII). Two hundred and eleven assessments were completed in 104 patients (67 males, mean age 55 y, range 18–86 y). There was very good external validity of the OMGRate: good correlation between OMGRate-e and MGC (r = 0.64, 95% confidence intervals [CI] 0.54–0.74, p < .0001); excellent correlation between OMGRate-q and MGII (r = 0.85, 95% CI 0.78–0.91, p < .0001) and good correlation between OMGRate and MG-QOL (r = 0.68, 95% CI 0.60–0.77, p < .0001). A higher correlation of OMGRate and MG-QOL compared with MGC and MG-QOL (r = 0.47, 95% CI 0.34–0.59, p < .0001) suggests that OMGRate is better able to capture significant QOL information in patients with OMG. It had excellent reliability with an intraclass correlation coefficient of 0.83 (95% CI 0.67–0.92). Feedback from examiners and patients indicated that the OMGRate was easy to use. In conclusion, OMGRate is an easy-to-use, valid and reliable rating scale for monitoring the severity of OMG.Keywords
This publication has 14 references indexed in Scilit:
- Ocular Myasthenia Gravis: Toward a Risk of Generalization Score and Sample Size Calculation for a Randomized Controlled Trial of Disease ModificationJournal of Neuro-Ophthalmology, 2016
- The MG‐QOL15 for following the health‐related quality of life of patients with myasthenia gravisMuscle & Nerve, 2010
- The MG CompositeNeurology, 2010
- Construct and concurrent validation of the MG‐QOL15 in the practice settingMuscle & Nerve, 2009
- Treatment of ocular symptoms in myasthenia gravisNeurology, 2008
- Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravisMuscle & Nerve, 2008
- Comparing Methods of Quantifying DiplopiaOphthalmology, 2007
- Perceptions of Recent Ophthalmology Residency Graduates Regarding Preparation for PracticeOphthalmology, 2007
- Validation and Test Characteristics of a 10-Item Neuro-Ophthalmic Supplement to the NEI-VFQ-25American Journal of Ophthalmology, 2006
- Myasthenia gravisNeurology, 2000